Increasing diagnosis and growing incidence & prevalence of cancer, technology advancements in therapeutics, increasing government initiatives globally are expected to drive the growth of the market in the coming years.

By application, the in situ hybridization market is categorized into cancer diagnosis, cytology, neuroscience, immunology and infectious diseases. The cancer diagnosis segment is expected to command the largest share of the global in situ hybridization market, by application in 2016. This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This is attributed to factors such as rising prevalence of cancer, increasing adoption of FISH in diagnosis of cancer, and rising demand for FISH-based companion diagnostics for cancer.

By technique, the market is categorized into fluorescent in situ hybridization (FISH) and chromogenic in situ hybridization (CISH). The FISH segment is expected to command the largest share of the global market, by technique in 2016. This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This can be attributed to factors such as like high resolution of this technique, rising adoption in research activities & laboratories to diagnose cancer, chromosomal abnormalities, and infectious diseases, among others.

Download PDF Brochure@ 
https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=212028829

On the basis of end users, the global in situ hybridization market is segmented into molecular diagnostic laboratories, academic & research institutes, contract research organizations, and pharmaceutical & biotechnology companies. In 2016, the molecular diagnostic laboratories segment is estimated to account for the largest share of the global in situ hybridization market, by end user. This segment is also projected to grow at the highest CAGR during the forecast period (2016-2021). This can be attributed to the availability of specialized skill sets in molecular diagnostic laboratories for ISH technique, rising prevalence of cancer coupled with genetic abnormalities, and increasing adoption of FISH in diagnosis of cancer and genetic abnormalities.

In the coming years, the market is expected to witness the highest growth in the Asia-Pacific region. This can be attributed to the growing presence of international players in China and India, increasing cancer prevalence and diagnosis, and increased healthcare expenditure across the Asia-Pacific region are drivers for the market in this region.

North America is expected to account for the largest share of the global market. This can be attributed to growing clinical and research in cancer by biotechnology and pharmaceutical companies, government initiatives, increasing prevalence and diagnosis of cancer in the U.S. and Canada, and increasing adoption of companion diagnostics. Increased adoption of Companion Diagnostics is attributed to the development and launch of newer therapeutic agents.

In the U.S., the in situ hybridization market is driven by increasing government initiatives, growing biomedical research, rising prevalence of cancer, and growing demand for companion diagnostics and personalized medicine.  In Canada, the growth of the market is driven by increased government funding and growing prevalence of cancer.

Read More@ 
https://www.marketsandmarkets.com/PressReleases/in-situ-hybridization.asp

The key strategies adopted by the major players include new product development, mergers & acquisitions, expansion, partnerships, agreements, and collaborations with other players in the in-situ hybridization landscape to meet the demand of their end users.

Major players operating in the global in-situ hybridization market are Abbott (U.S.), F. Hoffmann-La Roche Ltd (Switzerland), Affymetrix, Inc. (U.S.), Thermo Fisher Scientific, Inc. (U.S.), and Agilent Technologies, Inc. (U.S.).

About MarketsandMarkets™
MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model – GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Shelly Singh
MarketsandMarkets™ INC. 
630 Dundee Road 
Suite 430 
Northbrook, IL 60062 
USA : 1-888-600-6441 
[email protected]